This site is intended for healthcare professionals
News

Phase III ACTIVATE study of Pyrukynd in pyruvate kinase deficiency published in NEJM.- Agios Pharma

Read time: 1 mins
Published:15th Apr 2022

Pyrukynd is a first-in-class, oral PK activator and the first and only approved disease-modifying treatment for this rare, debilitating, lifelong hemolytic anemia.As reported in the publication, the ACTIVATE study met its primary endpoint, with 40 percent of patients randomized to Pyrukynd achieving a hemoglobin response, defined as a minimum 1.5 g/dL increase in hemoglobin concentration from baseline sustained at two or more scheduled assessments at Weeks 16, 20 and 24 during the fixed-dose period, compared to 0 patients randomized to placebo (2-sided p<0.001). patients who received pyrukynd had a significantly greater response than those who received placebo with respect to each secondary endpoint, including average change from baseline in hemoglobin level; average change from baseline in markers of hemolysis including indirect bilirubin, lactate dehydrogenase (ldh) and haptoglobin levels; average change from baseline in markers of hematopoietic activity (reticulocyte percentage); and change from baseline in two pk deficiency–specific patient-reported outcome measures.></0.001).>

The most common adverse events were nausea (in seven patients [18%] in the Pyrukynd group and nine patients [23%] in the placebo group) and headache (in six patients [15%] and 13 patients [33%], respectively). Adverse events of grade 3 or higher occurred in 10 patients (25%) who received Pyrukynd and five patients (13%) who received placebo.

See: "Mitapivat versus Placebo for Pyruvate Kinase Deficiency." Hanny Al-Samkari et al. N Engl J Med 2022; 386:1432-1442 April 14, 2022 DOI: 10.1056/NEJMoa2116634

Condition: Pyruvate Kinase Deficiency
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.